Bio-Techne (NASDAQ: TECH) reported Q2 EPS of $0.31, $0.18 worse than the analyst estimate of $0.49. Revenue for the quarter came in at $271.58 million versus the consensus estimate of $289.54 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.